A scoring system to predict molecular responses in patients with chronic myeloid leukemia in the chronic phase receiving initial imatinib therapy  

作　　者：李子郁 LI Ziyu(Peking Univ People's Hosp,Peking Univ Hematol Instit,Natl Clin Res Center,Hematol Dis,Beijing Key Lab,Hematopoietic Stem Cell Transplant,Beijing 100044)

机构地区：[1]Peking Univ People's Hosp,Peking Univ Hematol Instit,Natl Clin Res Center,Hematol Dis,Beijing Key Lab,Hematopoietic Stem Cell Transplant,Beijing 100044

出　　处：《China Medical Abstracts(Internal Medicine)》2023年第2期122-123,共2页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To develop a scoring system to predict molecular responses in patients with chronic myeloid leukemia in the chronic phase(CML-CP)receiving initial imatinib therapy.Methods Data from consecutive adults with newly diagnosed CML-CP treated by initial imatinib was interrogated and subjects were distributed randomly into training and validation cohort.

关 键 词：PATIENTS MYELOID IMATINIB 

分 类 号：R733.71[医药卫生—肿瘤]